高リン血症治療薬の世界市場:インサイト、市場機会、市場シェア、市場予測

◆英語タイトル:Global Hyperphosphatemia Drugs Market Insights, Opportunities, Analysis, Market Shares and Forecast 2016 – 2022
◆商品コード:OCCAM60717
◆発行会社(調査会社):Occams Research
◆発行日:2016年5月
◆ページ数:140
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,900 ⇒換算¥444,600見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD6,900 ⇒換算¥786,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はOccams Research社の日本における正規販売代理店です。Occams Research社の概要及び新刊レポートはこちらでご確認いただけます。
本調査レポートでは、世界の高リン血症治療薬市場について調査・分析し、市場インサイト、市場機会、市場シェア、市場規模予測などを含め、以下の構成でお届けいたします。
・高リン血症治療薬の世界市場:イントロダクション
・高リン血症治療薬の世界市場:市場概観
・高リン血症治療薬の世界市場:市場動向(促進要因、阻害要因、市場機会)
・高リン血症治療薬の世界市場:セグメント別市場分析
・高リン血症治療薬の世界市場:主要地域別市場分析
・高リン血症治療薬の世界市場:関連企業分析
【レポートの概要】

Hypophosphatemia predicted in patients who have an antiquity of starvation, anorexia/bulimia, alcoholism. Adequate cure comprises phosphate supplements along with feeding and care to causal eating disorders or substance exploitation. The global hypophosphatemia drugs market is driven by increasing aging population. According to WHO the world aged population by the end of 2050 is expected to reach 2 billion that is 900 million in 2015. Now Around 125 million people aged 80 years or more. By the end of 2050 almost 125 million people aged 80 years or more is expected to reach in China alone and 434 million people across the globe. Approximately 80% people live in low and middle income countries by the end of 2050. As the increasing aging population is one of the major driving factor of global hypophosphatemia drugs market.

The global Hypophosphatemia drugs market is estimated to see new heights during the forecasted period. The stringent government regulations and presence of alternatives are hampering the growth of Hypophosphatemia drugs in the global market. The untapped APAC region is creating the huge opportunities for the forecasted period in global Hypophosphatemia drugs market.

The Hypophosphatemia drugs is segmented on the basis of application, medical care and geography. The application segment is segmented into mineral supplements, vitamin D preparation and calcimimetic drugs. Medical care segment is further segmented into cause, severity and duration.

The global Hypophosphatemia drugs market is driven by the presence of some the prominent player in the market. Biotech Pharmacal, Cipla, DM Pharma, DSM, Johnson & Jhonson, Pfizer, Sun Pharm Inc. and UltraGenyx. The mergers, acquisition, innovation, product development are the key strategies adopted by key players to sustain into competitive market. may 11, 2016, Johnson & Johnson opens JLABS in Torronto, in which they are providing offoces, modular labs, access to industry capital funding. In this JLABS facility provide accommodations 50 startups and opens with 22 companies dealing in various sector in healthcare drug innovation.

On the basis of geography North America, Europe, Asia Pacific and RoW are the major segments. The Asia Pacific dominates the Hypophosphatemia drugs market with holding the largest market share. The large share is dominated by increasing aging population in the region. The rising osteoporosis in the APAC region is also driving the growth in the APAC market. the North America is the fastest growing region in the global market. the growth is majorly driven by the changing dietary habits in the region and increasing osteoporosis in the North America region.

【レポートの目次】

1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW
2.1. MARKET DEFINITION AND SCOPE
2.2. KEY FINDINGS
2.3. PARAMETRIC ANALYSIS
2.3.1. RAW MATERIAL SUPPLIER
2.3.2. PRODUCTION GEOGRAPHICALLY
2.3.3. ADOPTION ACROSS VARIOUS INDUSTRIES
2.4. KEY MARKET INSIGHTS
2.4.1. TOP 3 EMERGING COUNTRIES
2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
2.4.4. TOP 3 GEOGRAPHY
2.5. COMPETITIVE LANDSCAPE
2.5.1. MARKET SHARE ANALYSIS
2.5.2. TOP WINNING STRATEGIES
2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
2.6. PORTER’S FIVE FORCE MODEL
2.6.1. THREAT OF NEW ENTRANTS
2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
2.6.3. BARGAINING POWER OF BUYER
2.6.4. BARGAINING POWER OF SUPPLIER
2.6.5. INTENSITY OF COMPETITIVE RIVALRY
2.7. KEY BUYING CRITERIA
2.8. STRATEGIC RECOMMENDATION
2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. RISING AGING POPULATION
3.1.2. INCREASING OSTEOPOROSIS
3.1.3. CHANGING DIETARY HABITS
3.2. MARKET RESTRAINTS
3.2.1. STRINGENT FDA REGULATION
3.2.2. PRESENCE OF ALTERNATIVES
3.3. MARKET OPPORTUNITIES
3.3.1. UNTAPPED APAC REGIONS
3.4. MARKET CHALLENGES
3.4.1. SIDE EFFECTS ASSOCIATED WITH DRUGS
3.5. PARENT MARKET
3.6. COMPETITORS MARKET
3.7. ALTERNATIVE MARKET

4. MARKET SEGMENTATION
4.1. BY APPLICATION
4.1.1. GLOBAL MINERAL SUPPLEMENTS MARKET, 2014-2022 ($MILLIONS)
4.1.2. GLOBAL VITAMIN D PREPARATION MARKET,2014-2022 ($MILLIONS)
4.1.3. GLOBAL CALCIMIMETIC DRUGS MARKET,2014-2022 ($MILLIONS)
4.2. BY MEDICAL CARE
4.2.1. GLOBAL CAUSE MARKET, 2014-2022 ($MILLIONS)
4.2.2. GLOBAL SEVERITY MARKET,2014-2022 ($MILLIONS)
4.2.3. GLOBAL DURATION MARKET,2014-2022 ($MILLIONS)

5. GEOGRAPHICAL ANALYSIS
5.1. NORTH AMERICA HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.1.1. UNITED STATES (U.S.) HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.1.2. CANADA HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.2. EUROPE HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.2.1. UNITED KINGDOM (UK) HYPOPHOSPHATEMIA DRUGS MARKET, 2014-2022 ($MILLIONS)
5.2.2. FRANCE HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.2.3. GERMANY HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.2.4. SPAIN HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.2.5. ITALY HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.2.6. ROE HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.3. ASIA PACIFIC HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.3.1. INDIA HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.3.2. CHINA HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.3.3. JAPAN HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.3.4. AUSTRALIA HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.3.5. ROAPAC HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.4. REST OF THE WORLD HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022,($MILLIONS)
5.4.1. LATIN AMERICA HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.4.2. MENA HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
5.4.3. AFRICA HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)

6. COMPANY PROFILING: – (OVER, SCOT ANALYSIS, STRATEGIC REVIEW)
1. BIOTECH PHARMACAL
2. BRUNO FARMACEUTICI SPA
3. CIPLA
4. DM PHARMA
5. DSM
6. FERMENTA BIOTECH LTD.
7. JOHNSON & JHONSON
8. MOORE DRUGS CO.
9. PFIZER
10. ROCHE
11. SIEMENS
12. SUN PHARM INC
13. ULTRAGENYX
14. UPJOHN
15. ZERIA PHARMACEUTICAL

LIST OF TABLES
1. GLOBAL HYPOPHOSPHATEMIA DRUGS MARKET BY APPLICATION, 2014-2022 ($MILLIONS)
2. GLOBAL MINERAL SUPPLEMENTS MARKET, 2014-2022 ($MILLIONS)
3. GLOBAL VITAMIN D PREPARATION MARKET,2014-2022 ($MILLIONS)
4. GLOBAL CALCIMIMETIC DRUGS MARKET,2014-2022 ($MILLIONS)
5. GLOBAL HYPOPHOSPHATEMIA DRUGS MARKET BY MEDICAL CARE, 2014-2022 ($MILLIONS)
6. GLOBAL CAUSE MARKET, 2014-2022 ($MILLIONS)
7. GLOBAL SEVERITY MARKET,2014-2022 ($MILLIONS)
8. GLOBAL DURATION MARKET,2014-2022 ($MILLIONS)
9. NORTH AMERICA HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022, ($MILLIONS)
10. EUROPE HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022, ($MILLIONS)
11. ASIA PACIFIC HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022, ($MILLIONS)
12. REST OF THE WORLD HYPOPHOSPHATEMIA DRUGS MARKET,2014-2022, ($MILLIONS)

LIST OF FIGURES
1. GLOBAL HYPOPHOSPHATEMIA DRUGS MARKET BY APPLICATION, 2014-2022 ($MILLIONS)
2. GLOBAL MINERAL SUPPLEMENTS MARKET, 2014-2022 ($MILLIONS)
3. GLOBAL VITAMIN D PRECREATION MARKET,2014-2022 ($MILLIONS)
4. GLOBAL CALCIMIMETIC DRUGS MARKET,2014-2022 ($MILLIONS)
5. GLOBAL HYPOPHOSPHATEMIA DRUGS MARKET BY MEDICAL CARE, 2014-2022 ($MILLIONS)
6. GLOBAL CAUSE MARKET, 2014-2022 ($MILLIONS)
7. GLOBAL SEVERITY MARKET,2014-2022 ($MILLIONS)
8. GLOBAL DURATION MARKET,2014-2022 ($MILLIONS)



【レポートのキーワード】

高リン血症治療薬、ミネラル補給剤、ビタミンD調合、カルシウム受容体作動薬

★調査レポート[高リン血症治療薬の世界市場:インサイト、市場機会、市場シェア、市場予測]販売に関する免責事項
★調査レポート[高リン血症治療薬の世界市場:インサイト、市場機会、市場シェア、市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆